The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade1-3

Oct 8, 2024
1 min read

Click here to learn more and register!

Recent Posts

See All

Advocate for Change Join the Massachusetts Biomarker Testing Coalition Lobby Day, NEXT WEEK May 13th

NEW Event! From Mutation to Management: Practical Nursing Strategies in HER2-Mutant NSCLC ~ 5.14.26 @ ONS Congress

Management of high-risk non-melanoma skin cancers (NMSC)

Dear BONS Membes, I’d like to invite you to join a Dana-Farber–anchored, multidisciplinary CME activity focused on the management of high-risk non-melanoma skin cancers (NMSC)—including BCC, cSCC, and

Comments